- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03824561
Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Ulcerative Colitis]
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this survey is called vedolizumab for IV infusion 300 mg. This drug is being tested to treat patients who have UC.
This survey is an observational (non-interventional) study and will look at the long-term safety and effectiveness of vedolizumab for IV infusion 300 mg in the routine clinical setting. The planned number of observed patients will be approximately 1,000.
This multi-center observational trial will be conducted in Japan.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Takeda Contact
- Phone Number: +1-877-825-3327
- Email: medinfoUS@takeda.com
Study Locations
-
-
-
Tokyo, Japan
- Takeda Selected Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have moderate or severe active UC
- Have inadequate response to existing therapies
Exclusion Criteria:
Patients with any contraindication for vedolizumab
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Vedolizumab 300 mg
Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks.
Participants will receive IV infusion as part of routine medical care.
|
Vedolizumab IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants who have One or More Adverse Events
Time Frame: Up to Week 54
|
Adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
|
Up to Week 54
|
Number of Participants who have One or More Adverse Drug Reactions
Time Frame: Up to Week 54
|
AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Adverse drug reaction refers to AE related to administered drug.
|
Up to Week 54
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants who have a Presence or Absence of Therapeutic Response After 3 Doses of Vedolizumab
Time Frame: After 3 doses of vedolizumab (Week 6 to 14)
|
After 3 doses of vedolizumab (Week 6 to 14)
|
|
Number of Participants who continue the Therapy After 3 Doses of Vedolizumab
Time Frame: After 3 doses of vedolizumab (Week 6 to 14)
|
After 3 doses of vedolizumab (Week 6 to 14)
|
|
Change from Baseline in Complete Mayo Scores
Time Frame: Baseline and after 3 doses of vedolizumab (Week 6 to 14), and Week 54
|
Mayo score is used to assess UC disease activity.
It consists of 4 sub-scores (stool frequency, rectal bleeding, findings on sigmoidoscopy, and physician's global assessment), each ranges from 0 to 3. Complete Mayo score sums 4 sub-scores and ranges from 0 to 12, with higher scores indicating more severe disease.
|
Baseline and after 3 doses of vedolizumab (Week 6 to 14), and Week 54
|
Change from Baseline in Partial Mayo Scores
Time Frame: Baseline and after 3 doses of vedolizumab (Week 6 to 14), and Week 54
|
Mayo score is used to assess UC disease activity.
It consists of 4 sub-scores (stool frequency, rectal bleeding, findings on sigmoidoscopy, and physician's global assessment), each ranges from 0 to 3. Partial Mayo score sums 3 sub-scores excluding the sigmoidoscopy sub-score and ranges from 0 to 9, with higher scores indicating more severe disease.
|
Baseline and after 3 doses of vedolizumab (Week 6 to 14), and Week 54
|
Change from Baseline in Quality of Life (QOL) Assessment using Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time Frame: Baseline and after 3 doses of vedolizumab (Week 6 to 14), and Week 54
|
The SIBDQ is an instrument used to assess quality of life and is a disease-specific health-related quality of life questionnaire, that consists of 10 questions, each question is scored on a scale from 1 (poor quality of life) to 7 (good quality of life).
The total score will be reported and is ranging from 10 to 70 with a higher score indicates a better health-related quality of life.
|
Baseline and after 3 doses of vedolizumab (Week 6 to 14), and Week 54
|
Change from Baseline in Fecal Calprotectin
Time Frame: Baseline and multiple time points up to Week 54
|
Baseline and multiple time points up to Week 54
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director, Takeda
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vedolizumab-5033
- jRCT1080224534 (Registry Identifier: jRCT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Vedolizumab
-
Universita degli Studi di GenovaWithdrawn
-
TakedaWithdrawnCrohn's Disease | Ulcerative Colitis
-
TakedaCompleted
-
TakedaActive, not recruitingCrohn's Disease | Colitis, UlcerativeUnited States, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Netherlands, Australia, Denmark, Hungary, Italy, Russian Federation, Brazil, Croatia, Germany, Serbia, Bulgaria, Canada, Poland, Slovakia, Ukraine, Czechia, Argentina, Turke... and more
-
Ced Service GmbHRecruitingInflammatory Bowel Diseases | TreatmentGermany
-
TakedaCompletedCrohn's DiseaseBelgium, Israel, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Hungary, Serbia, Bulgaria, Canada, Germany, Italy, Poland, Slovakia, Czechia, Mexico, Romania, Brazil, Estonia, United States, Bosnia and Herzegovina and more
-
Mayo ClinicWithdrawnUlcerative Colitis | Dietary ModificationUnited States
-
TakedaRecruitingCrohn's DiseaseChina
-
TakedaCompletedCrohn Disease | Ulcerative ColitisIndia